Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
2023.
Tocilizumab.
Reactions Weekly,
Vol. 1954,
Issue. 1,
p.
408.
Published online by Cambridge University Press: 14 May 2021
We evaluated adverse drug events (ADEs) by chart review in a random national sample of 428 veterans with coronavirus disease 2019 (COVID-19) who received tocilizumab (n = 173 of 428). ADEs (median time, 5 days) occurred in 51 of 173 (29%) and included hepatoxicity (n = 29) and infection (n = 13). Concomitant medication discontinuation occurred in 22% of ADE patients; mortality was 39%.